Officially opened in 2022, the new “MARS Centre” (MARS) at Tai Po INNOPARK is dedicated to the manufacturing of medical supplies such as high-quality surgical masks and personal protection equipment (“PPE”), medical devices and related equipment. Such products demand superior levels of precision, hygiene and higher quality at all levels of the production cycle. MARS is “built-to-fit” for advanced industries and aspirational industrialists keen to leverage Hong Kong’s R&D, talent and international standards to run critical processes and scale up production.

SkyPro is honored to be invited to be one of the tenants of the MARS, citing our past outstanding achievements in the production of medical consumables, including technology, research and development, production and other professional models. In the same year, we set up the first fully automated mask production line at the above site. With the help of our self-developed purchasing mobile app and smart warehouse management system, we can fully automate the process from customer ordering to completion of production and delivery, greatly improving production efficiency.

We are committed to the mission of “Innofacturing”, and will continue to apply and improve existing applications of advanced I&T technologies such as Artificial Intelligence and Robotics, Data Analysis and the Internet of Things, reflecting Hong Kong’s growing advanced manufacturing capabilities.

The “built-to-fit” features of SkyPro’s manufacturing factory at MARS include:

• • Certified ISO-8 clean rooms
  • Compressed air supply
  • 24-hour AC chilled water supply
  • Industrial 3-phase power supply
  • Epoxy floor
  • Floor loading of 7.5 kPa for industrial equipment

Our Existing Xiamen Production Base had a GFA of approximately 113,600 sq.m. in aggregate and it housed an ISO 8 Cleanroom with GFA of over 88,000 sq.m., warehouses with GFA of over 17,000 sq.m., and were equipped with 168 production lines for masks. During the Track Record Period, our production sites provided an annual/quarterly production volume of approximately 545.1 million pieces, 1,063.6 million pieces, 383.0 million pieces and 241.1 million pieces of masks for FY2019, FY2020, FY2021 and 4M2022, respectively. We expect to relocate our production facilities from our Existing Xiamen Production Base to our New Medical Product Production Plant starting from 2023 and upgrade our existing production lines to become automated production lines to further enhance our operational efficiency.

We had also assembled five raw material production lines in our Existing Xiamen Production Base for manufacturing melt-blown non-woven fabric. As non-woven fabric is a key filtering layer of masks, we wish to set up non-woven fabric production lines to allow us to manufacture raw materials, thereby achieving stable supply and efficient delivery of the same for our production and retaining the flexibility to design and configure our production lines to fit our uses. However, apart from melt-blown non-woven fabric, there are various raw materials required for the manufacturing of our masks and other medical consumables. Therefore, we plan to construct the New Raw Material Production Plant to guarantee stable supply of other key raw materials required in our production including spunbond non-woven fabric, ear-loops and noseclips.